Evaluation of akathisia in patients receiving selective serotonin reuptake inhibitors/serotonin and noradrenaline reuptake inhibitors.

IF 1.6 4区心理学 Q3 BEHAVIORAL SCIENCES

Behavioural Pharmacology Pub Date : 2024-12-01 Epub Date: 2024-10-08 DOI:10.1097/FBP.0000000000000797

Ismail Akgoz, Huseyin Kara, Ozgen Ozcelik, Levent Donmez, Mehmet Eryilmaz, Gul Ozbey

{"title":"Evaluation of akathisia in patients receiving selective serotonin reuptake inhibitors/serotonin and noradrenaline reuptake inhibitors.","authors":"Ismail Akgoz, Huseyin Kara, Ozgen Ozcelik, Levent Donmez, Mehmet Eryilmaz, Gul Ozbey","doi":"10.1097/FBP.0000000000000797","DOIUrl":null,"url":null,"abstract":"<p><p>Akathisia is an underestimated but disturbing extrapyramidal side effect of antidepressants, which could reduce treatment compliance in mood disorders. This study aimed to investigate the frequency and risk factors in patients treated with selective serotonin reuptake inhibitors/serotonin and noradrenaline reuptake inhibitors (SSRI/SNRI). In addition, we assessed the impact of akathisia on the quality of life (QoL). Patients were aged between 18 and 75 years, receiving an SSRI/SNRI for 4-8 weeks, and were diagnosed with anxiety, depression, or obsessive-compulsive disorder. The Barnes Akathisia Rating Scale was used to assess the severity of the akathisia. QoL was evaluated using the Short Form 36 (SF-36) questionnaire. Akathisia was observed in 25% (50/198) of patients. Smokers and younger patients were more frequent among patients with akathisia. Physical functioning, physical role, vitality, and mental health domains of the SF-36 were reduced in the presence of akathisia. In conclusion, our results suggest that akathisia is not a rare side effect of SSRI/SNRI in patients with mood disorders, especially in smokers and younger patients. In addition, akathisia may reduce treatment compliance owing to a reduction in QoL. Further investigations are needed to confirm the risk factors, frequency, and consequences of treatment compliance for SSRI/SNRI-induced akathisia in patients with mood disorders.</p>","PeriodicalId":8832,"journal":{"name":"Behavioural Pharmacology","volume":" ","pages":"460-463"},"PeriodicalIF":1.6000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Behavioural Pharmacology","FirstCategoryId":"102","ListUrlMain":"https://doi.org/10.1097/FBP.0000000000000797","RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BEHAVIORAL SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Akathisia is an underestimated but disturbing extrapyramidal side effect of antidepressants, which could reduce treatment compliance in mood disorders. This study aimed to investigate the frequency and risk factors in patients treated with selective serotonin reuptake inhibitors/serotonin and noradrenaline reuptake inhibitors (SSRI/SNRI). In addition, we assessed the impact of akathisia on the quality of life (QoL). Patients were aged between 18 and 75 years, receiving an SSRI/SNRI for 4-8 weeks, and were diagnosed with anxiety, depression, or obsessive-compulsive disorder. The Barnes Akathisia Rating Scale was used to assess the severity of the akathisia. QoL was evaluated using the Short Form 36 (SF-36) questionnaire. Akathisia was observed in 25% (50/198) of patients. Smokers and younger patients were more frequent among patients with akathisia. Physical functioning, physical role, vitality, and mental health domains of the SF-36 were reduced in the presence of akathisia. In conclusion, our results suggest that akathisia is not a rare side effect of SSRI/SNRI in patients with mood disorders, especially in smokers and younger patients. In addition, akathisia may reduce treatment compliance owing to a reduction in QoL. Further investigations are needed to confirm the risk factors, frequency, and consequences of treatment compliance for SSRI/SNRI-induced akathisia in patients with mood disorders.

查看原文本刊更多论文

评估接受选择性 5-羟色胺再摄取抑制剂/5-羟色胺和去甲肾上腺素再摄取抑制剂治疗的患者的抽搐症状。

肌张力障碍是抗抑郁药物的一种被低估但却令人不安的锥体外系副作用，它可能会降低情绪障碍患者的治疗依从性。本研究旨在调查接受选择性 5-羟色胺再摄取抑制剂/5-羟色胺和去甲肾上腺素再摄取抑制剂（SSRI/SNRI）治疗的患者出现副作用的频率和风险因素。此外，我们还评估了无运动症状对生活质量（QoL）的影响。患者年龄在 18 岁至 75 岁之间，接受过 4-8 周的 SSRI/SNRI 治疗，被诊断为焦虑症、抑郁症或强迫症。采用巴恩斯运动障碍评定量表评估运动障碍的严重程度。QoL 采用简表 36 (SF-36) 问卷进行评估。25%的患者（50/198）出现了运动障碍。在有抽搐症状的患者中，吸烟者和年轻患者较多。出现激越时，SF-36 中的身体功能、身体角色、活力和心理健康领域均有所下降。总之，我们的研究结果表明，在情绪障碍患者中，尤其是在吸烟者和年轻患者中，抽搐并不是 SSRI/SNRI 的罕见副作用。此外，肌无力可能会降低患者的生活质量，从而降低治疗依从性。需要进行进一步研究，以确认情绪障碍患者中由 SSRI/SNRI 引起的运动障碍的风险因素、发生频率和治疗依从性的后果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Behavioural Pharmacology 医学-行为科学

CiteScore

3.40

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Behavioural Pharmacology accepts original full and short research reports in diverse areas ranging from ethopharmacology to the pharmacology of schedule-controlled operant behaviour, provided that their primary focus is behavioural. Suitable topics include drug, chemical and hormonal effects on behaviour, the neurochemical mechanisms under-lying behaviour, and behavioural methods for the study of drug action. Both animal and human studies are welcome; however, studies reporting neurochemical data should have a predominantly behavioural focus, and human studies should not consist exclusively of clinical trials or case reports. Preference is given to studies that demonstrate and develop the potential of behavioural methods, and to papers reporting findings of direct relevance to clinical problems. Papers making a significant theoretical contribution are particularly welcome and, where possible and merited, space is made available for authors to explore fully the theoretical implications of their findings. Reviews of an area of the literature or at an appropriate stage in the development of an author’s own work are welcome. Commentaries in areas of current interest are also considered for publication, as are Reviews and Commentaries in areas outside behavioural pharmacology, but of importance and interest to behavioural pharmacologists. Behavioural Pharmacology publishes frequent Special Issues on current hot topics. The editors welcome correspondence about whether a paper in preparation might be suitable for inclusion in a Special Issue.